Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 880

Sort by

Sort Order Select

Journal Articles

Treatment of Delayed Hemolytic Transfusion Reactions in Sickle Cell Disease Patients By an Anti-C5 Antibody

Blood (2019) 134 (Supplement_1): 2458.

https://doi.org/10.1182/blood-2019-127176

Published: 2019

Journal Articles

Heterozygous Mutations of Clpb As a Newly Identified and Frequent Cause of Severe Congenital Neutropenia

Julia T Warren, MD PhD, Peeradol Wattanasirakul, David H Spencer, MD, Adam Locke, PhD, Vahagn Makaryan, MD, Audrey Anna Bolyard, RN, BS, Karl Welte, Julia Skokowa, MD PhD, David C. Dale, MD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 433.

https://doi.org/10.1182/blood-2019-129635

Published: 2019

Journal Articles

Immune Reconstitution in 107 Children with Sickle Cell Anemia Transplanted with Bone Marrow or Cord Blood from a Matched-Sibling Donor after Myeloablative Conditioning Regimen Including 20mg/Kg ATG

Francoise Bernaudin, MD, Azadeh Djavidi, MD, Cécile Arnaud, MD, Annie Kamdem, MD, Isabelle Hau, MD, Corinne Pondarré, MD PhD, Jean-Paul Vernant, MD, Mathieu Kuentz, MD, Nathalie Dhedin, MD, Jean-Hugues Dalle, MD PhD, Eliane Gluckman, Gerard Socie, MD PhD

Blood (2019) 134 (Supplement_1): 2253.

https://doi.org/10.1182/blood-2019-125316

Published: 2019

Journal Articles

Loss of Heterozygosity in the Short Tandem Repeat (STR) Loci Found in Tumor DNA of De Novo Diagnosed ALL Patients As a Factor Predicting Poor Outcome

Natalya V Risinskaya, PhD, Olga A. Gavrilina, MD PhD, Julia A. Chabaeva, Anna Yushkova, Andrey B Sudarikov, PhD DSc, Sergei M. Kulikov, PhD, Elena N. Parovichnikova, MD PhD, Valery G. Savchenko, MD PhD academician

Blood (2019) 134 (Supplement_1): 5204.

https://doi.org/10.1182/blood-2019-126668

Published: 2019

Journal Articles

Maintenance Therapy in Patients with Chronic Lymphocytic Leukemia Who Achieved MRD-Positive Remissions after Induction Therapy

Alexey Kuvshinov, MD, Sergei Voloshin, MD PhD, Vasily Shuvaev, MD, Elena Belyakova, MD, Mariia Mikhaleva, MD, Andrey Garifullin, MD, Georgiy Rysev, MD, Alexander Bogdanov, MD PhD, Irina Martynkevich, MD PhD, Elizaveta Kleina, Alena Samorodova, MD, Iuliia Ruzhenkova, Iuliia Vokueva, Alexander Chechetkin

Blood (2019) 134 (Supplement_1): 5475.

https://doi.org/10.1182/blood-2019-129995

Published: 2019

Journal Articles

Haploidentical Stem Cell Transplantation in Advanced Stage Mycosis Fungoides and Sézary Syndrome: A Report of Four Consecutive Cases from a Single Center

Francesco Onida, MD, Giorgia Saporiti, MD, Viviana Beatrice Valli, MD, Silvia Alberti Violetti, MD, Federica Irene Grifoni, MD, Maria Cecilia Goldaniga, MD, Mariarita Sciumè, MD, Luca Baldini, MD PhD, Emilio Berti, MD

Blood (2019) 134 (Supplement_1): 5744.

https://doi.org/10.1182/blood-2019-131501

Published: 2019

Journal Articles

Comparable Leukemic Cells Reduction but Improved Normal Hematopoietic Regeneration with G-CSF Priming Plus Low Dose Chemotherapy Regimen Relative to Standard Chemotherapy in AML Mice Model

Ya Zhang, MS, Xiaomin Feng, MD PhD, Aili Chen, PhD, Shaoyan Hu, MD PhD, Qianfei Wang, PhD, Gang Huang, PhD

Blood (2019) 134 (Supplement_1): 1362.

https://doi.org/10.1182/blood-2019-129465

Published: 2019

Journal Articles

Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients

John E. Godwin, MD, Carmen Ballesteros-Merino, PhD, Nikhil Lonberg, Shawn Jensen, PhD, Tarsem Moudgil, Carlo B Bifulco, MD, Jon Wigginton, MD, John Muth, MS, Jan K Davidson-Moncada, MD PhD, Bernard Fox, PhD

Blood (2019) 134 (Supplement_1): 1410.

https://doi.org/10.1182/blood-2019-128485

Published: 2019

Journal Articles

Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 1609.

https://doi.org/10.1182/blood-2019-131499

Published: 2019

Journal Articles

Safety and Efficacy of First Line Venetoclax Combinations in AML Patients Ineligible for Intensive Therapy, a Real World Data

Arie Apel, MD, Yishay Ofran, MD, Avraham Frisch, MD, Yakir Moshe, MD, Ofir Wolach, MD, Chiya Leibovitch, MD, Natalia Kreiniz, MD, Maya Koren-Michowitz, MD

Blood (2019) 134 (Supplement_1): 3902.

https://doi.org/10.1182/blood-2019-125720

Published: 2019

Journal Articles

Oral Arsenic Trioxide in Front Line Therapy for Acute Promyelocytic Leukemia. A Prospective Costa Rican Study

Mariela Rodriguez, MD, Ronald Rojas, Alejandra Vargas, MD, Miguel Angel Rodriguez, MD, Claudia Garcia, MD, Juliana Esquivel, MD, Jose Gerardo Rojas, MD, Willem Bujan Boza, MD

Blood (2019) 134 (Supplement_1): 3838.

https://doi.org/10.1182/blood-2019-122627

Published: 2019

Journal Articles

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Colleen Annesley, MD, Corinne Summers, MD, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Julie Rivers, MD, Adam J. Lamble, MD, Ashley Wilson, PhD, Qian Vicky Wu, PhD, Adam Brand, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD, Rebecca Gardner, MD

Blood (2019) 134 (Supplement_1): 3869.

https://doi.org/10.1182/blood-2019-131447

Published: 2019

Journal Articles

Efficacy and Safety of a FLAG-Sequential Regimen Followed By Hematopoietic Stem Cell Transplantation for Myelodysplasia or Acute Leukemia in Fanconi Anemia: A Franco-Brazilian Report

Pierre-Edouard Debureaux, Flore Sicre de Fontbrune, Carmem M. S. Bonfim, MD, Jean-Hugues Dalle, MD PhD, Nimrod Buchbinder, MD, Yves Bertrand, MD, Cecile Renard, MD, Edouard Forcade, MD, Juliana Fernandes, MD, Alexis Talbot, MD, Ricardo Pasquini, MD, Jean Soulier, MD PhD, Thierry Leblanc, MD, Gerard Socie, MD PhD, Regis Peffault de Latour, MD PhD

Blood (2019) 134 (Supplement_1): 2498.

https://doi.org/10.1182/blood-2019-122007

Published: 2019

Journal Articles

Subcutaneous Alemtuzumab Has Activity in Treatment-Naïve Patients with Acquired Aplastic Anemia

Ana Rita Da Fonseca, MD, Anita Hill, MD PhD, Patricia Eiko Yamakawa, MD, Iara Baldim Rabelo, MD PhD, Andre Domingues Pereira, MD, Vinicius Campos de Molla, MD, Matheus Vescovi Gonçalves, MD PhD, Morag Griffin, MD, Talha Munir, MD, Peter Hillmen, MD PhD, Louise Arnold, MD, Kathryn Riley, MD, Antonio M. Risitano, MD PhD, Phillip Scheinberg, MD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 2503.

https://doi.org/10.1182/blood-2019-130719

Published: 2019

Journal Articles

Demonstration of the Safety of Post Induction Infusion of Ex-Vivo Expanded Cord Blood Progenitor Cells in Pediatric Patients with Relapsed/Refractory Acute Myelogenous Leukemia

Ann Dahlberg, MD, Muna Qayed, MDMSc, Katherine Tarlock, MD, Jessica A. Pollard, MD, Filippo Milano, MD PhD, Soheil Meshinchi, MD PhD, Colleen Delaney, MD MSc

Blood (2019) 134 (Supplement_1): 2614.

https://doi.org/10.1182/blood-2019-130979

Published: 2019

Journal Articles

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Blood (2019) 134 (Supplement_1): 2642.

https://doi.org/10.1182/blood-2019-129137

Published: 2019

Journal Articles

Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia

Michael T Byrne, DO, Nathalie Danielson, MSN, Adrianne Rasche, MSN, Rachel Hammers, MSN, Kathryn A Culos, PharmD, Katie S Gatwood, PharmD, Houston Wyatt, PharmD, Kristin Fogo, BSN, Bhagirathbhai Dholaria, MBBS, Brian G Engelhardt, MD, Paul Brent Ferrell, Jr., MD, Madan Jagasia, MBBS, MS, MMHC, Adetola A. Kassim, MDMS, Sanjay R Mohan, MD MSCI, Bipin N. Savani, MD, Stephen A. Strickland, MD, Salyka M. Sengsayadeth, MD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2643.

https://doi.org/10.1182/blood-2019-129146

Published: 2019

Journal Articles

High Rates of Varicella Zoster Virus Antibody Seroconversion after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients Undergoing Active Treatment

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD,MPH,PhD, John P Galvin, MDMS,MPH, Damiano Rondelli, MD, Pritesh Patel, MB, ChB

Blood (2019) 134 (Supplement_1): 3081.

https://doi.org/10.1182/blood-2019-131914

Published: 2019

Journal Articles

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Christopher Pleyer, MD, Jeffrey Cohen, MD, Susan Soto, Mir Ali, PhD, Inhye E Ahn, MD, Pia Nierman, BSN, MA, RN, Janet Valdez, Jennifer Lotter, PA-C, Jeanine Superata, RN, Xin Tian, Adrian Wiestner, MD PhD, Clare Sun, MD

Blood (2019) 134 (Supplement_1): 3053.

https://doi.org/10.1182/blood-2019-121675

Published: 2019

Journal Articles

Prediction for the Risk of Gvhd after Allogeneic HSCT in Patients with ATL Treated By Mogamulizumab

Yuhei Kamada, MD PhD, Ayako Kuroki, PhD, Naosuke Arima, MD, Maiko Hayashida, MD, Daisuke Nakamura, MD PhD, Makoto Yoshimitsu, MD PhD, Kenji Ishitsuka, MD PhD

Blood (2019) 134 (Supplement_1): 3290.

https://doi.org/10.1182/blood-2019-126912

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Treatment of Delayed Hemolytic Transfusion Reactions in Sickle Cell Disease Patients By an Anti-C5 Antibody

Heterozygous Mutations of Clpb As a Newly Identified and Frequent Cause of Severe Congenital Neutropenia

Immune Reconstitution in 107 Children with Sickle Cell Anemia Transplanted with Bone Marrow or Cord Blood from a Matched-Sibling Donor after Myeloablative Conditioning Regimen Including 20mg/Kg ATG

Loss of Heterozygosity in the Short Tandem Repeat (STR) Loci Found in Tumor DNA of De Novo Diagnosed ALL Patients As a Factor Predicting Poor Outcome

Maintenance Therapy in Patients with Chronic Lymphocytic Leukemia Who Achieved MRD-Positive Remissions after Induction Therapy

Haploidentical Stem Cell Transplantation in Advanced Stage Mycosis Fungoides and Sézary Syndrome: A Report of Four Consecutive Cases from a Single Center

Comparable Leukemic Cells Reduction but Improved Normal Hematopoietic Regeneration with G-CSF Priming Plus Low Dose Chemotherapy Regimen Relative to Standard Chemotherapy in AML Mice Model

Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients

Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Safety and Efficacy of First Line Venetoclax Combinations in AML Patients Ineligible for Intensive Therapy, a Real World Data

Oral Arsenic Trioxide in Front Line Therapy for Acute Promyelocytic Leukemia. A Prospective Costa Rican Study

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Efficacy and Safety of a FLAG-Sequential Regimen Followed By Hematopoietic Stem Cell Transplantation for Myelodysplasia or Acute Leukemia in Fanconi Anemia: A Franco-Brazilian Report

Subcutaneous Alemtuzumab Has Activity in Treatment-Naïve Patients with Acquired Aplastic Anemia

Demonstration of the Safety of Post Induction Infusion of Ex-Vivo Expanded Cord Blood Progenitor Cells in Pediatric Patients with Relapsed/Refractory Acute Myelogenous Leukemia

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia

High Rates of Varicella Zoster Virus Antibody Seroconversion after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients Undergoing Active Treatment

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Prediction for the Risk of Gvhd after Allogeneic HSCT in Patients with ATL Treated By Mogamulizumab

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only